RecruitingNot Applicable

A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity

United States100 participantsStarted 2024-02-08

Plain-language summary

To learn about the relationship between changes in pupil size and reactivity and the start of neurological side effects in patients after receiving CAR-T cell therapy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Ages Eligible for Study: 18 Years and above (Adult, Older Adult)
✕. Sexes Eligible for Study: All
✕. Patient with histologically proven DLBCL, PMBCL or tFL, or follicular Lymphoma receiving axi-cel CAR-T cell therapy in the inpatient setting at MD Anderson Cancer Center
✕. Ability to understand and the willingness to sign a written informed consent document.
✕. Patients who have already been administered CAR-T cell therapy.
✕. The patient who is unwilling or unable to comply with the requirements of the study including being able to be assessed with pupillometer
✕. Patient has a condition which places him at an unacceptable risk as determined by the investigator

What they're measuring

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Timeframe: Through study completion; an average of 1 year.

Trial details

NCT IDNCT06144151

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-04-01

Contact for this trial

Ranjit Nair, MD

(713) 563-4354 rnair@mdanderson.org

View on ClinicalTrials.gov More Neurotoxicity trials